A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to generate defence proteins, which are then transferred to the foetus through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from birth
- Coverage achievable with two-week gap before premature birth
- Vaccination during the third trimester still offers meaningful protection for infants
Strong evidence from recent research
The effectiveness of the pregnancy RSV vaccine has been confirmed through a comprehensive study undertaken in England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that six-month period, providing strong and reliable evidence of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and expectant parents with assurance in the vaccine’s proven efficacy across different groups and contexts.
The results paint a notable picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme introduced in the UK in 2024.
Study design and parameters
The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection rates and hospital admissions. The substantial sample size and thorough nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology measured practical outcomes rather than laboratory-based settings, providing real-world data of how the vaccine functions when given across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests rising whilst they try to pull adequate oxygen into their weakened respiratory system. Whilst most infants recover with clinical support, a limited though important group succumb from respiratory syncytial virus complications yearly, making prevention through vaccination a essential public health objective for safeguarding the youngest and most vulnerable people in our communities.
- RSV produces inflammation in lungs, causing serious respiratory problems in infants
- Half of all infants acquire the virus during their first few months alive
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- A small number of infants die from RSV related complications annually in the UK
Uptake rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the value of pregnant women getting their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to get their vaccine as early as possible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The messaging from public health bodies stays clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to pregnant women that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to increase awareness and access to the jab. These regional differences reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows consistently strong protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in vaccination coverage levels throughout England require targeted improvement
- Community health services tailoring initiatives to suit specific population needs
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness delivers concrete gains for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV before the rollout of this preventative solution, the 80% drop in admissions equates to thousands of infants shielded from critical disease. Parents no longer face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that mark critical RSV illness. The vaccine has fundamentally shifted the picture of neonatal lung health, giving expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in profound brain damage, the vaccine’s introduction carries significant emotional significance. His mother’s promotion of the jab emphasises the profound consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has offered substantial reassurance to pregnant women in their late pregnancy, converting what was once an predictable seasonal threat into a manageable risk.